Stock Events

ARCA biopharma 

€2.78
31
+€0+0% Today

Statistics

Day High
2.78
Day Low
2.78
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
43.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

19JulExpected
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
-0.14
-0.12
-0.1
-0.08
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HQ10.F. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biotech firm that develops cardiovascular drugs, competing directly with ARCA's heart failure treatments.
Pfizer
PFE
Mkt Cap169.83B
Pfizer develops a wide range of medications including those for cardiovascular diseases, directly competing with ARCA's portfolio.
Novartis
NVS
Mkt Cap232.42B
Novartis is a global healthcare company that offers products in various therapeutic areas including cardiology, competing with ARCA's heart-related therapies.
Merck &
MRK
Mkt Cap318.55B
Merck produces medications for various conditions, including heart diseases, making it a competitor in the cardiovascular space.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb develops a range of prescription medicines, including those for cardiovascular diseases, competing with ARCA.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences focuses on antiviral drugs and other medications, including heart disease treatments, competing with ARCA.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie, a research-based biopharmaceutical company, has a portfolio that includes cardiovascular drugs, competing with ARCA.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for cardiovascular diseases, competing with ARCA.
Sanofi
SNY
Mkt Cap128.21B
Sanofi focuses on healthcare solutions including cardiovascular diseases, directly competing with ARCA's therapeutic area.

About

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Show more...
CEO
Dr. Michael R. Bristow M.D., Ph.D.
Employees
4
Country
US
ISIN
US00211Y5069
WKN
000A2PGY6

Listings

XNAS
US
ABIO
F
DE
HQ10.F